Blindness is one of the most feared health hazards in our present society; millions of Europeans are threatened by blinding untreatable eye diseases producing costs of several billion Euros. EVI aims at devising and implementing programs and projects for new therapeutic strategies for eye diseases that are difficult or impossible to be treated presently. Its approach will incorporate the most recent scientific developments of the postgenomic area.
The European Vision Institute should be of enormous strategic importance for the future and is targeted towards more immediate policy objectives of improving the competitiveness of European Research assembling the top institutes together with partners from industry and academia. EVI integrates, conducts and supports research that helps to prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages.
Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma” In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology Read more
Researchers at the University and the University Hospital of Bonn have developed a method that could be used to diagnose atherosclerosis. Using self-learning software, they were able to identify vascular changes in patients with peripheral arterial disease (PAD), often at an early stage. Read more
Authors in low-income countries rarely published free-to-read papers, even when they qualified for publication-fee waivers. Read more
The company completed enrollment ahead of schedule in a second Phase 3 FDA registration trial for Nyxol in RM with top-line results expected by the end of the first quarter. Read more
The Toronto-based medical eyewear company partnered with the visual assistance community to help empower an Oregon college student with enhanced vision. Read more
The "Gateway to European Vision Research" is a web-based portal service for the European vision research community and major stakeholders.
An award and public recognition by any measure is a sign of inimitability - an acknowledgment that peers and professionals alike agree that a certain person excels in what they do.
Read more about the European Vision Award and the Carl Zeiss Young Investigator Award.
Ophthalmic Research - The Journal for Translational and Clinical Research is official affiliated with the European Vision Institute